Background Non-alcoholic fatty liver disease, or as recently proposed 'metabolic-associated
fatty liver disease'(MAFLD), is characterized by pathological accumulation of triglycerides …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in
lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its …

Proprotein convertase subtilisin/kexin type 9 (PCSK9), mainly synthetized and released by
the liver, represents one of the key regulators of low-density lipoprotein cholesterol …

Aims PCSK9 is secreted into the circulation, mainly by the liver, and interacts with low-
density lipoprotein receptor (LDLR) homologous and non-homologous receptors, including …

Clinical trials have unequivocally shown that inhibition of proprotein convertase
subtilisin/kexin type 9 (PCSK9) efficaciously and safely prevents cardiovascular events by …

Abstract Purpose of Review Plasma levels of LDL cholesterol (LDL-C) are causally
associated with cardiovascular risk. Reducing LDL-C results in a decreased incidence of …

Introduction There are inconsistent findings regarding the effect of lipid-lowering agents on
nonalcoholic fatty liver disease (NAFLD). Proprotein Convertase Subtilisin/Kexin type 9 …

Previous investigations have shown molecular cross-talk among activated adenosine
monophosphate-activated protein kinase (AMPK), proprotein convertase subtilisin/kexin …

Background and aims Nonalcoholic fatty liver disease (NAFLD) may be crucial in subjects
with familial hypercholesterolemia (FH). We aimed to evaluate the effect of the inhibitors of …

Abstract Purpose of Review Proprotein convertase subtilisin kexin 9 (PCSK9) plays a crucial
role in regulating circulating levels of LDL-C as a consequence of its ability to inhibit LDL …